Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program

被引：0
|
作者：
Xin Du
Jie Jin
Zhen Cai
Fangping Chen
Dao-bin Zhou
Li Yu
Xiaoyan Ke
Xiao Li
Depei Wu
Fanyi Meng
Dena DeMarco
Jingshan Zhang
Jay Mei
Jian Hou
机构：
[1] Guangdong General Hospital,The 1st Affiliated Hospital
[2] Zhejiang University,Department of Hematology
[3] Xiangya Hospital of Central South University,undefined
[4] Peking Union Medical College Hospital,undefined
[5] The 301 Hospital-Chinese PLA General Hospital,undefined
[6] Peking University Third Hospital,undefined
[7] Shanghai 6th Hospital,undefined
[8] The 1st Affiliated Hospital of Soochow University,undefined
[9] Nanfang Hospital of Southern Medicine University in Guangzhou,undefined
[10] Celgene Corporation,undefined
[11] Shanghai Changzheng Hospital,undefined
来源：
BMC Cancer | / 16卷
关键词：
Relapsed/refractory multiple myeloma; Chinese patients; Lenalidomide; Low-dose dexamethasone; Dexamethasone;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] A Phase 1/2 Trial of Low-Dose Continuous Azacitidine in Combination with Lenalidomide and Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma
    Khouri, Jack
    Faiman, Beth
    Wei, Wei
    Grabowski, Dale
    Samaras, Christy Joy
    Mahfouz, Reda
    Lazarus, Hillard
    Dean, Robert
    Malek, Eshan
    Reed, Janice
    Karam, Mary Ann
    Hamilton, Kimberly
    Rosko, Nathaniel
    Fada, Sherry
    Kalaycio, Matt
    Liu, Hien
    Saunthararajah, Yogen
    Chew, Yap
    Valent, Jason
    Reu, Frederic
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E262 - E263
  • [32] A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial
    Jian Hou
    Xin Du
    Jie Jin
    Zhen Cai
    Fangping Chen
    Dao-bin Zhou
    Li Yu
    Xiaoyan Ke
    Xiao Li
    Depei Wu
    Fanyi Meng
    Huisheng Ai
    Jingshan Zhang
    Honeylet Wortman-Vayn
    Nianhang Chen
    Jay Mei
    Jianmin Wang
    Journal of Hematology & Oncology, 6
  • [33] A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial
    Hou, Jian
    Du, Xin
    Jin, Jie
    Cai, Zhen
    Chen, Fangping
    Zhou, Dao-bin
    Yu, Li
    Ke, Xiaoyan
    Li, Xiao
    Wu, Depei
    Meng, Fanyi
    Ai, Huisheng
    Zhang, Jingshan
    Wortman-Vayn, Honeylet
    Chen, Nianhang
    Mei, Jay
    Wang, Jianmin
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6
  • [34] Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma
    Bahlis, Nizar J.
    Sutherland, Heather
    White, Darrell
    Sebag, Michael
    Lentzsch, Suzanne
    Kotb, Rami
    Venner, Christopher P.
    Gasparetto, Cristina
    Del Col, Aldo
    Neri, Paola
    Reece, Donna
    Kauffman, Michael
    Shacham, Sharon
    Unger, T. J.
    Jeha, Jacqueline
    Saint-Martin, Jean-Richard
    Shah, Jatin
    Chen, Christine
    BLOOD, 2018, 132 (24) : 2546 - 2554
  • [35] Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM): Keynote-023
    San Miguel, Jesus
    Mateos, Maria-Victoria
    Shah, Jatin J.
    Ocio, Enrique M.
    Rodriguez-Otero, Paula
    Reece, Donna
    Munshi, Nikhil C.
    Avigan, David
    Ge, Yang
    Balakumaran, Arun
    Marinello, Patricia
    Orlowski, Robert Z.
    Siegel, David
    BLOOD, 2015, 126 (23)
  • [36] Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma: A phase I/II study
    Lonial, S.
    Vij, R.
    Harousseau, J.
    Facon, T.
    Moreau, P.
    Leleu, X.
    Westland, C.
    Singhal, A. K.
    Jagannath, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [37] Elotuzumab In Combination with Lenalidomide and Low-Dose Dexamethasone In Patients with Relapsed/Refractory Multiple Myeloma: Interim Results of a Phase 1 Study
    Lonial, Sagar
    Vij, Ravi
    Harousseau, Jean-Luc
    Facon, Thierry
    Moreau, Philippe
    Leleu, Xavier
    Mazumder, Amitabha
    Kaufman, Jonathan L.
    Westland, Christopher E.
    Tsao, Claire
    Singhal, Anil K.
    Jagannath, Sundar
    BLOOD, 2010, 116 (21) : 805 - 806
  • [38] Long-term responses observed with lenalidomide therapy for patients with relapsed or refractory multiple myeloma
    Jagannath, S.
    Richardson, P. G.
    Zeldenrust, S.
    Alsina, M.
    Wride, K.
    Zeldis, J. B.
    Knight, R.
    Olesnyckyj, M.
    Anderson, K. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [39] CYTOGENETICS AND LONG-TERM SURVIVAL IN MM-003, A PHASE 3 TRIAL OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE VS. HIGH-DOSE DEXAMETHASONE IN REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
    Dimopoulos, M. A.
    Weisel, K.
    Song, K. W.
    Delforge, M.
    Karlin, L.
    Goldschmidt, H.
    Moreau, P.
    Banos, A.
    Oriol, A.
    Garderet, L.
    Cavo, M.
    Ivanova, V.
    Alegre, A.
    Martinez-Lopez, J.
    Chen, C. I.
    Spencer, A.
    Knop, S.
    Bahlis, N. J.
    Renner, C.
    Yu, X.
    Hong, K.
    Sternas, L.
    Jacques, C.
    Zaki, M. H.
    San Miguel, J. F.
    HAEMATOLOGICA, 2014, 99 : 365 - 365
  • [40] REAL WORLD USE OF IXAZOMIB WITH LENALIDOMIDE AND DEXAMETHASONE FOR PATIENTS WITH RELAPSED AND RELAPSED REFRACTORY MULTIPLE MYELOMA
    Ziff, M.
    Cheesman, S.
    Kyriakou, C.
    Mehta, A.
    Papanikolaou, X.
    Rabin, N.
    Wechalekar, A.
    Yong, K.
    Popat, R.
    HAEMATOLOGICA, 2017, 102 : 786 - 787
12345